

Children's Mercy Kansas City

SHARE @ Children's Mercy

Manuscripts, Articles, Book Chapters and Other Papers

7-2019

The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.

Nicole L. Prokopishyn

Brent R. Logan

Deidre M. Kiefer

Jennifer A. Sees

Pintip Chitphakdithai

See next page for additional authors

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/papers>



Part of the [Hematology Commons](#)

Recommended Citation

Prokopishyn NL, Logan BR, Kiefer DM, et al. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. *Biol Blood Marrow Transplant.* 2019;25(7):1325-1330. doi:10.1016/j.bbmt.2019.01.034

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Creator(s)

Nicole L. Prokopishyn, Brent R. Logan, Deidre M. Kiefer, Jennifer A. Sees, Pintip Chitphakdithai, Ibrahim A. Ahmed, Paolo N. Anderlini, Amer M. Beitinjaneh, Christopher Bredeson, Jan Cerny, Saurabh Chhabra, Andrew Daly, Miguel Angel Diaz, Nosha Farhadfar, Haydar A. Frangoul, Siddhartha Ganguly, Dennis A. Gastineau, Usama Gergis, Gregory A. Hale, Peiman Hematti, Rammurti T. Kamble, Kimberly A. Kasow, Hillard M. Lazarus, Jane L. Liesveld, Hemant S. Murthy, Maxim Norkin, Richard F. Olsson, Mona Papari, Bipin N. Savani, Jeffrey Szer, Edmund K. Waller, Baldeep Wirk, Jean A. Yared, Michael A. Pulsipher, Nirali N. Shah, Galen E. Switzer, Paul V. O'Donnell, Dennis L. Confer, and Bronwen E. Shaw



Biology of Blood and Marrow Transplantation

journal homepage: www.bbmt.org



The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time



Nicole L. Prokopishyn¹, Brent R. Logan^{2,3}, Deidre M. Kiefer⁴, Jennifer A. Sees⁴, Pintip Chitphakdithai⁴, Ibrahim A. Ahmed⁵, Paolo N. Anderlini⁶, Amer M. Beitinjaneh⁷, Christopher Bredeson⁸, Jan Cerny⁹, Saurabh Chhabra¹⁰, Andrew Daly¹¹, Miguel Angel Diaz¹², Nosha Farhadfar¹³, Haydar A. Frangoul¹⁴, Siddhartha Ganguly¹⁵, Dennis A. Gastineau¹⁶, Usama Gergis¹⁷, Gregory A. Hale¹⁸, Peiman Hematti¹⁹, Rammurti T. Kamble²⁰, Kimberly A. Kasow²¹, Hillard M. Lazarus²², Jane L. Liesveld²³, Hemant S. Murthy¹³, Maxim Norkin¹³, Richard F. Olsson^{24,25}, Mona Papari²⁶, Bipin N. Savani²⁷, Jeffrey Szer²⁸, Edmund K. Waller²⁹, Baldeep Wirk³⁰, Jean A. Yared³¹, Michael A. Pulsipher³², Nirali N. Shah³³, Galen E. Switzer³⁴, Paul V. O'Donnell³⁵, Dennis L. Confer^{4,36}, Bronwen E. Shaw^{2,*}

¹ Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada

² Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

³ Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin

⁴ Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota

⁵ Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, Missouri

⁶ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

⁷ Department of Hematology, University of Miami, Miami, Florida

⁸ The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, ON, Canada

⁹ Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts

¹⁰ Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

¹¹ Tom Baker Cancer Center, Calgary, Alberta, Canada

¹² Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain

¹³ Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, Florida

¹⁴ Division of Pediatric-Hematology and Oncology, The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, Tennessee

¹⁵ Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas

¹⁶ Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota

¹⁷ Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, New York

¹⁸ Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida

¹⁹ Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin

²⁰ Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas

²¹ Department of Pediatrics in the Division of Hematology-Oncology, University of North Carolina, Chapel Hill, North Carolina

²² Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland, Ohio

²³ Strong Memorial Hospital-University of Rochester Medical Center, Rochester, New York

²⁴ Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden

²⁵ Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden

²⁶ IxM Clinical Services Cord Blood Lab, Rosemont, Illinois

²⁷ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

²⁸ Clinical Haematology at Peter MacCalluma Cancer Centre and The Royal Melbourne Hospital, Victoria, Australia

²⁹ Department of Hematology and Medical Oncology, Emory University Hospital, Atlanta, Georgia

³⁰ Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington

³¹ Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland

³² Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California

³³ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

³⁴ Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

³⁵ Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

³⁶ National Marrow Donor Program/Be The Match, Minneapolis, Minnesota

Financial disclosure: See Acknowledgments on page 1330.

* Correspondence and reprint requests: Bronwen E. Shaw, MBChB, PhD,

9200 West Wisconsin Avenue, Suite C5500, Milwaukee, WI 53226

E-mail addresses: beshaw@mcw.edu, bshaw@doctors.org.uk (B.E. Shaw).

<https://doi.org/10.1016/j.bbmt.2019.01.034>

1083-8791/© 2019 American Society for Blood and Marrow Transplantation.

Article history:

Received 5 November 2018

Accepted 29 January 2019

Key Words:

Unrelated donor

Bone marrow

Total nucleated cells

A B S T R A C T

Bone marrow (BM) is an essential source of hematopoietic stem cell grafts for many allogeneic hematopoietic cell transplant (HCT) recipients, including adult patients (for specific diseases and transplantation strategies) and the majority of pediatric recipient. However, since the advent of granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) grafts, there has been a significant decrease in the use of BM in HCT, thought to be due mainly to the increased logistical challenges in harvesting BM compared with PBSCs, as well as generally no significant survival advantage of BM over PBSCs. The decreased frequency of collection has the potential to impact the quality of BM harvests. In this study, we examined >15,000 BM donations collected at National Marrow Donor Program centers between 1994 and 2016 and found a significant decline in the quality of BM products, as defined by the concentration of total nucleated cells (TNCs). The mean TNC concentration in BM donations dropped from 21.8×10^6 cells/mL in the earliest era (1994 to 1996) to 18.7×10^6 cells/mL in the most recent era (2012 to 2016) (means ratio, .83; $P < .001$). This decline in BM quality was seen despite the selection of more donors perceived to be optimal (eg, younger and male). Multivariate regression analysis showed that higher-volume centers (performing >30 collections per era) had better-quality harvests with higher concentrations of TNCs collected. In conclusion, we have identified a significant decrease in the quality of BM collections over time, and lower-volume collection centers had poorer-quality harvests. In this analysis, we could not elucidate the direct cause for this finding, suggesting the need for further studies to investigate the key factors responsible and to explore the impact on transplant recipients.

© 2019 American Society for Blood and Marrow Transplantation.

INTRODUCTION

Bone marrow (BM) is the original, and an essential, hematopoietic stem cell (HSC) source for many allogeneic hematopoietic cell transplantation (HCT) recipients. However, with the advent of granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) transplants, and given the logistical advantages of PBSC collection over BM collection, significant decreases in the use of BM have occurred at many transplantation centers. Since the introduction of PBSCs, the use of BM as the HSC source in the unrelated donor setting has declined from 100% in the early 1990s to 19% in 2017 [1]. Nonetheless, BM remains the preferred cell source for specific disease indications in adults (eg, aplastic anemia), for the majority of pediatric transplants, and when the benefits of a decreased risk of chronic graft-versus-host disease (GVHD) outweigh other considerations [2–4]. Indeed, several studies have demonstrated that recipients of BM grafts experience less chronic GVHD than recipients of PBSC grafts [2,5,6]. In addition, other studies have shown that pediatric patients receiving BM have a survival advantage over patients receiving PBSCs [3,7,8]. The recent use of HLA-mismatched and haploidentical transplants at some centers and in current clinical trials has also led to an increased use of BM in these settings, owing to a presumed increased risk of GVHD overall with these transplants [9,10].

The decreased use of BM in allogeneic HCT has several potential consequences, including negatively affecting the overall quality of BM donations owing to a lack of experience with the harvesting procedure at both center and operator levels. Although standard operating procedures are in place and centers provide initial training, ongoing competency assessment is often difficult when few procedures are performed per year in many centers. The Foundation for Accreditation of Cellular Therapies (FACT) standard requires the BM harvest team of an accredited facility to perform at least 1 BM harvest per year average in the accreditation cycle (ie, a minimum of 3 BM harvests in the accreditation cycle of 3 years), to perform quality assessment of collection procedures, and to implement standardized protocols [11]. However, FACT standards do not address individual collector experience, a minimum number of collections per individual collector per year, specific staff training, and collection techniques. In addition, proper assessment of BM harvest metrics, including total nucleated cell (TNC) dose collected compared with target dose, quality of BM collected, and adverse reactions in donors following collection, is

difficult in an individual collection center when limited procedures are performed, and comparable evaluations from other centers are not easily obtained.

In a single-center study, quality measurements found decreasing TNC doses over time in BM products collected externally and received for individual patients (personal communication, N. Prokopishyn, Jan 2008). We sought to confirm and explore potential reasons for this observation in a validation cohort. Thus, the aim of this study was to examine the trends in BM harvest quality in a large cohort of National Marrow Donor Program (NMDP) donors over several decades to establish whether this single-center observation could be generalized. To this end, we assessed the BM quality (defined as concentration of TNC per BM volume collected) in harvests performed by NMDP centers between 1994 and 2016. In addition to the number of harvests per center per era, other donor and procedure factors were examined to evaluate their impact on BM quality.

METHODS**Study Population**

The study population comprised domestic unrelated first-time BM donors of products collected at NMDP centers between 1994 and 2016. Data on donor and donation characteristics were recorded on standard data forms by the NMDP. All donors included in this study provided written informed consent for participation in Center for International Blood and Marrow Transplant Research (CIBMTR) studies that were approved by the NMDP's Institutional Review Board.

BM Donation

BM was collected in an operating room from the posterior iliac crests under general or regional anesthesia in accordance with NMDP standards. NMDP standards mandate aspiration of no more than 20 mL/kg (donor weight) of marrow, a duration of anesthesia not to exceed 150 minutes, and a duration of collection <120 minutes [12].

Data Collection

All data used in our analysis were reported by collection centers to the NMDP/CIBMTR at the time of collection/transplantation. The number of collections per center per era was calculated using the number of collections reported to the NMDP in this population.

Endpoints

The primary study outcome was the measurement of TNCs collected per milliliter of BM as an estimate of HSC product quality. For each harvest, this was calculated based on TNCs in the product and the volume of the final product, including additives. The calculation was performed before any processing at the transplantation center. The number of collections performed per harvest center and era was also determined.

Statistical Methods

The study population was analyzed over 5 eras: 1994 to 1996, 1997 to 2001, 2002 to 2006, 2007 to 2011, and 2012 to 2016. Eras were selected to represent 5 years per period, except for the first era, which covers only 3 years, 1994 to 1996, because before 1994, insufficient data were available for analysis. A variety of donor characteristics, including sex, age, and body mass index (BMI), as well as collection volume with and without additives per donor weight, were compared between eras using the chi-square test. Donor weight, duration of anesthesia, duration of the collection procedure, product volume with additive, and TNC concentration in the BM product were compared using the Kruskal-Wallis test. Collection centers were subdivided based on collection center volume per harvest center per era. High-volume centers were defined as centers collecting ≥ 30 BM products per center per era; low-volume centers, as those collecting < 30 BM products per center per era.

For multivariate analysis, log transformation was applied to TNC concentrations to induce normality. Multiple linear regression was used to model log TNC concentrations as a function of the primary variable of interest (era of donation), as well as donor characteristics (ie, sex, race, age, and weight) and the number of donations per harvest center per era. Stepwise variable selection was used to select variables in addition to the primary variable of interest. Interactions between the primary variable of interest and the other covariates were assessed. Effects are summarized as ratios of means of the TNC concentrations, owing to the use of log transformation for modeling. We also investigated accounting for potential harvest center effects through the use of linear mixed models, including a random effect for harvest center; however, we found no significant center effect, and the results were not meaningfully impacted by adjusting for random center effects, and so those results were omitted from our analysis.

RESULTS

More than 15,000 BM donations collected between 1994 and 2016 were examined in this study. Donor, collection, and product data are provided in Table 1. We found a significant decline in the mean concentration of TNCs in the BM products over time, from 21.8×10^6 TNCs/mL in the earliest era (1994 to 1996) to 18.7×10^6 TNCs/mL in the most recent era (2012 to 2016) (means ratio, .83; $P < .001$) (Table 2 and Figure 1).

In recent eras, BM donors were significantly more likely to be young ($P < .001$) and male ($P < .001$) (Table 1). In the 2012 to 2016 era, 54% of the donors were age < 30 , compared with only 25% in 1994 to 1996 and 1997 to 2001. Similarly, 65% of the donors were male in the 2012 to 2016 era, compared with 53% in 1994 to 1996 era. Moreover, there was a significant difference in donor weight over time, with donors in the 2012 to 2016 era weighing more than donors in earlier eras (Figure 2). Univariate analysis of recipient weight found significant differences over time as well (Figure 3).

The number of centers performing collections varied from a high of 106 centers in the 1997 to 2001 era to a low of 73 centers in the most recent era examined, 2012 to 2016 (Table 1). Similarly, the highest number of total BM collections was recorded in the 1997 to 2001 era. However, the mean number of collections per center was highest in the 2012 to 2016 era. The average number of collections per era increased over the last 3 eras (Table 1) even though the number of collection centers performing BM harvests declined.

Multivariate analysis confirmed the impact of era on reduced BM quality over time, with a ratio of means TNC concentration of .83 in 2012 to 2016 compared with 1994 to 1996 (95% confidence interval [CI], .81 to .84; $P < .001$) (Table 3). Donor race was also found to be associated with a reduction in BM quality over time, with significantly lower TNC doses in Hispanic, African/African American, and Asian Pacific Islander donors compared with Caucasian donors (mean ratio, .98 [95% CI, .96 to .99], .85 [95% CI, .84 to .87], and .90 [95% CI, .88 to .92], respectively). Older donors had lower BM quality with compared to the youngest donors (age 18 to 29 years). Donor factors associated with increased BM quality included female sex (mean ratio compared with male donors, 1.04; 95% CI, 1.03 to 1.06), and donor weight, with better quality in heavier donors. The heaviest donor group,

weighing > 83 kg, had a mean ratio of 1.14 compared with the lightest donors weighing ≤ 69 kg (95% CI, 1.12 to 1.16). The number of BM collections at a center per era was also associated with BM quality, with centers performing ≥ 30 collections per era having a significantly better correlation with BM quality compared with centers performing < 30 collections per era (mean ratio, 1.02; 95% CI, 1.01 to 1.04) (Table 3, Figure 4).

DISCUSSION

In this large study of unrelated BM donor harvests, we found a significant decrease in the quality of BM products over time, as demonstrated by a drop in the TNC dose collected in recent years. Interestingly, these results were found despite the increased use of what are considered optimal donors (eg, younger males) in more recent eras [13–16]. The use of younger male donors has been linked to higher TNC doses in BM products in some studies [14,16]; however, this was not found in our study, in which lower BM quality was associated with male sex. Older age and all other races except Caucasian and Native American were associated with lower TNC doses collected. Although there was a change in racial diversity of the donor population over time, with a reduction from 81% Caucasian in the earliest era to 61% Caucasian in the most recent era, racial diversity is not likely responsible for the decreasing TNC doses over time, given that even with adjustments for race in the multivariate model, the effect remained significant. Donor weight > 69 kg was associated with higher BM quality. Interestingly, we noted an increase in donor weight in the recent era. However, this increase in donor weight and its purported positive effects on BM quality did not prevent the significant decline in BM quality in the current era. As such, shifts in donor types used in BM collection today do not explain the observed decline in TNC concentration. Unfortunately, approximately 34% of donors did not have an associated recipient weight reported, and thus no conclusions could be drawn regarding the impact of time on the TNC dose collected per kilogram of recipient weight. The reduction in recipient weight seen in the later eras may be a result of an increased proportion of the BM products used in pediatric recipients.

Multivariate analysis showed that volume of collection center BM harvests may play a crucial role in BM quality, as we found that higher-volume collection centers collected higher-quality BM products. Specifically, collection centers that collect ≥ 30 BM products per era collect higher-quality products than those centers collecting < 30 BM products per era (Figure 4). Therefore, factors such as collector experience, collection center policies and procedures, collection team training/continuing competency, and collection technique may play significant roles. Indeed, Fagioli et al [17] spoke to the importance of collector training and standardized procedures in the quality of BM harvested. In low-volume centers, the number of harvests performed per collector may be insufficient to maintain the appropriate level of expertise in BM procedures.

In addition, specific technical aspects of the BM collection, which differ from center to center, may have a profound influence on the TNC concentrations collected. For example, the speed of the collection and harvest draws can impact the concentration collected, with faster collections yielding lower TNC concentrations [14,18]. The speed of collection can be influenced both by harvester technique and the type of needle used in the collection [18,19]. In addition, some studies have suggested that large-volume collections and longer collection times can decrease the likelihood of obtaining the desired TNC dose [20,21]. Furthermore, larger aspirate volumes have been shown to produce decreased TNC and CD34⁺ cell counts compared with smaller aspirate volumes [20,22,23]. Indeed,

Table 1
Donor, Collection, and Product Data by Era

Variable	1994-1996	1997-2001	2002-2006	2007-2011	2012-2016*	P Value [†]
Number of donors	1720	4439	3135	2999	3583	
Number of centers	90	106	91	80	73	
Sex, n (%)						<.001
Female	806 (47)	2026 (46)	1263 (40)	1164 (39)	1267 (35)	
Male	914 (53)	2413 (54)	1872 (60)	1835 (61)	2316 (65)	
Race, n (%)						<.001
Caucasian	1400 (81)	3235 (73)	2318 (74)	1999 (67)	2174 (61)	
Hispanic	109 (6)	472 (11)	291 (9)	357 (12)	516 (14)	
African/African American	94 (5)	294 (7)	200 (6)	194 (6)	270 (8)	
Asian/Pacific Islander	63 (4)	240 (5)	134 (4)	181 (6)	215 (6)	
Native American	19 (1)	74 (2)	48 (2)	36 (1)	28 (1)	
Multiple/other	19 (1)	94 (2)	121 (4)	210 (7)	352 (10)	
Unknown/declined	16 (1)	30 (1)	23 (1)	22 (1)	28 (1)	
Age at donation, yr						<.001
18-29, n (%)	424 (25)	1089 (25)	927 (30)	1175 (39)	1946 (54)	
30-39, n (%)	640 (37)	1600 (36)	1060 (34)	917 (31)	939 (26)	
40-49, n (%)	514 (30)	1357 (31)	867 (28)	690 (23)	519 (14)	
50+, n (%)	142 (8)	393 (9)	281 (9)	217 (7)	179 (5)	
Median (range)	37 (19-58)	37 (19-61)	36 (19-61)	33 (19-61)	29 (19-60)	<.001
Weight, kg						
Number evaluated	1720	4439	3135	2999	3583	
Median (range)	76 (26-175)	79 (9-200)	82 (14-193)	82 (40-164)	81 (41-150)	<.001
Collection-related variables						
Duration of anesthesia, min						
Number evaluated	0	0	1546	2987	1682	
Median (range)	(-)	(-)	90 (26-248)	92 (25-355)	88 (34-301)	.042
Duration of collection, min						
Number evaluated	0	0	1559	2989	1686	
Median (range)	(-)	(-)	55 (7-194)	51 (2-208)	48 (0-221)	<.001
Product-related variables						
Collection volume, without additives, L						<.001
<1, n (%)	0	0	689 (44)	1302 (44)	1490 (42)	
1-1.5, n (%)	0	0	695 (44)	1304 (44)	1424 (40)	
≥1.5, n (%)	0	0	181 (12)	370 (12)	606 (17)	
Unknown, n (%)	1720 (N/A)	4439 (N/A)	1570 (N/A)	23 (N/A)	63 (N/A)	
Median (range)	(-)	(-)	1064 (68-2360)	1067 (119-2323)	1090 (125-2214)	<.001
Collection volume with additive per donor weight, mL/kg						<.001
<10	0	0	482 (31)	898 (30)	1029 (29)	
10- <15	0	0	490 (31)	984 (33)	1033 (29)	
15- <20	0	0	519 (33)	904 (30)	1087 (31)	
≥20	0	0	74 (5)	190 (6)	371 (11)	
Unknown	1720 (N/A)	4439 (N/A)	1570 (N/A)	23 (N/A)	63 (N/A)	
Median (range)	(-)	(-)	13.1 (7-23.6)	13.1 (1.2-29.0)	13.6 (1.3-40.2)	<.001
Product volume, with additive, mL						
Number evaluated	1718	4424	3127	2993	3550	
Median (range)	1200 (91-2782)	1257 (180-3110)	1266 (128-2767)	1246 (139-2557)	1290 (108-2720)	<.001

N/A indicates not applicable.

Helgestad et al [24] reported that small-volume marrow aspirates provide more representative BM results with less blood contamination. Interestingly, our data show that the volume of BM collected increased while the duration of the harvest decreased in the latest era. Previous studies have indicated that larger product volumes are being collected in short time periods, most likely to obtain the requested cell dose for recipients [25]. Although a shorter collection time is beneficial and associated with reduced adverse reactions in donors [26], it

may negatively affect the product quality [27], [28] suggesting that a compromise between these extremes may be optimal. Whether the decreased TNC concentrations observed in our study were the result of larger aspirates obtained during harvesting is unknown, given that aspirate volume and speed of draw were not reported. Moreover, the type of needle used for BM collection was not reported, and thus it is impossible to determine the influence of harvesting equipment and supplies on our findings.

Table 2
Concentration of TNCs with Additive over Time

Variable	1994-1996	1997-2001	2002-2006	2007-2011	2012-2016	P Value
Number of donors	1720	4439	3135	2999	3583	
Number of centers	90	106	91	80	73	
Concentration of TNCs with additive, × 10 ⁶ /mL						
Number evaluated	1718	4420	3121	2989	3547	
Median (range)	21.8 (4.3-3450.0)	20.3 (4.3-2400.0)	19.8 (3-1320.0)	19.5 (3.1-16,236.7)	18.7 (1.2-349.8)	<.001




Figure 1. Median concentration of TNCs with additive, $\times 10^6$ cells/mL, by era of collection and collection center size.




Figure 2. Donor weight increased significantly over time ($P < .001$). Data are for the 1st percentile, lower quartile, median, upper quartile, and 99th percentile by examined eras.




Figure 3. Reduction in weight of BM recipients over time. Data are median, with 1st percentile, lower quartile, upper quartile, and 99th percentile. $N = 10,437$; associated recipient weight data were available for only 66% of the donors.

Furthermore, details regarding collector experience, technique, training, and staff turnover were not available. Further studies examining the collection process, including training, techniques, equipment, and donor characteristics, will help elucidate the entire process and aid the identification of strategies aimed at improving the quality of BM products collected. For example, examination of the role of educational tools, such as the NMDP’s BM collection video, and their impact on technique standardization would be beneficial to determine whether specific variables can help improve BM quality. In addition, the consolidation of BM harvests into centralized “super centers” may affect many of these variables and address several concerns, although such super centers might not be feasible in many settings. Interestingly, the number of centers performing BM harvests has decreased by more than 30% since




Figure 4. Number of collections per year by era, with mean (x) and median (♦) values. The maximum number of collections performed per year in the era is represented numerically, with the box representing the 25th and 75th percentiles. The arrows indicate the maximum number of collections per era, which are >60 (230 for 1994-1996, 477 for 1997-2001, 479 for 2007-2011, and 920 for 2012-2016) and are not represented, to more accurately depict the difference in quartile values across eras.

Table 3
Multivariate Model Using Linear Regression on Log TNC Concentration

Variable	Relative Effect (Relative Change in TNC Concentration)	95% CI	P Value
Collection year			
1994-1996	1.00		<.001
1997-2001	.92	.90-.93	<.001
2002-2006	.89	.87-.90	<.001
2007-2011	.87	.86-.89	<.001
2012-2016	.83	.81-.84	<.001
Donor race			
Caucasian	1.00		<.001
Hispanic	.98	.96-.99	.003
African/African American	.85	.84-.87	<.001
Asian Pacific Islander	.90	.88-.92	<.001
Native American	1.04	.99-1.09	.083
Multiple race/other	.97	.95-.99	.014
Unknown/declined to answer	.92	.87-.97	.003
Donor sex			
Male	1.00		<.001
Female	1.04	1.03-1.06	<.001
Number of collections per center			
<30	1.00		<.001
≥ 30	1.02	1.01-1.04	<.001
Donor age at collection			
18-29	1.00		<.001
30-39	.98	.97-.99	<.001
40-49	.92	.91-.93	<.001
50+	.89	.87-.91	<.001
Donor weight, kg			
≤ 69	1.00		<.001
69-71	1.04	1.01-1.07	.004
71-83	1.07	1.05-1.09	<.001
83+	1.14	1.12-1.16	<.001

the peak of 106 centers in 1997 to 2001 (Table 1). However, it is unknown how many of the collections were performed by these centers that no longer perform collections.

In conclusion, we found that the quality of BM harvests has decreased over time, and that collection centers performing smaller numbers of BM harvests per year collect lower-quality

BM products. This decline in BM quality has persisted even though centers have been using more optimal donors in recent eras. Further studies are needed to elucidate the factors responsible for this significant decrease in BM quality and, critically, to determine the impact of this declining BM quality on transplantation outcomes, to ensure that BM remains a high-quality source of HSCs for HCT.

ACKNOWLEDGMENTS

Financial disclose: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement [5U24CA076518](#) from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement [1U24HL138660](#) from the NHLBI and NCI; Contract [HSH250201700006C](#) with the Health Resources and Services Administration; Grants [N00014-17-1-2388](#), [N00014-17-1-2850](#), and [N00014-18-1-2045](#) from the Office of Naval Research; and grants from Adaptive Biotechnologies, *Amgen, anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be The Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology, *Celgene, *Chimerix, *CytoSen Therapeutics, Fred Hutchinson Cancer Research Center; Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Karius, Karyopharm Therapeutics, *Kite Pharma, Medac, *Mediware, The Medical College of Wisconsin, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, Mundipharma EDO, National Marrow Donor Program; Novartis Pharmaceuticals, PCORI, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, Swedish Orphan Biovitrum, *Takeda Oncology, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government.

*Corporate members

Conflict of interest statement: There are no conflicts of interest to report.

Authorship statement: N.L.P.: study conception and design, literature search, data interpretation, manuscript writing and review; B.R.L, D.M.K., J.A.S.: study design, data collection, data analysis, figure and table generation, manuscript writing and review; P.C.: study design, data interpretation, manuscript review; I.A., P.A., A.B., C.B., J.C., S.C., D.L.C., A.D., M.A.D., N.F., H. F., S.G., D.G., U.G., G.H., P.H., R.K., K.K., H.L., J.L., H.M., M.N., P.V. O., R.O., M.P., M.A.P., B.S., N.N.S., G.E.S., J.S., E.W., B.W., and J.Y.: study design, literature review, manuscript writing and review; B.E.S.: study design, literature search, data interpretation, manuscript writing and review.

REFERENCES

- World Marrow Donor Association. WMDA global trend report. 2017. Available at: <https://www.wmda.info/wp-content/uploads/2018/06/20180531-GTR-Graphs-2017-Summary.pdf>. Accessed 14 February 2019.
- Campregher PV, Hamerschlak N, Colturato VA, et al. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients. *Eur J Haematol*. 2015;95:421–425.
- Holtick U, Albrecht M, Chemnitz JM, et al. Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults—a systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2015;94:179–188.
- Kumar R, Kimura F, Ahn KW, et al. Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions. *Biol Blood Marrow Transplant*. 2016;22:932–940.
- Pulsipher MA, Chitphakdiithai P, Logan BR, et al. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donations. *Blood*. 2014;123:3655–3663.
- Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. *Biol Blood Marrow Transplant*. 2007;13:1461–1468.
- Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringdén O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. *Blood*. 2005;105:548–551.
- Eapen M. Unrelated donor transplantation: peripheral blood or bone marrow—does it matter? *Best Pract Res Clin Haematol*. 2014;27:278–282.
- Shinzato A, Tabuchi K, Atsuta Y, et al. PB SCT is associated with poorer survival and increased chronic GVHD than BMT in Japanese paediatric patients with acute leukemia and an HLA-matched sibling donor. *Pediatr Blood Cancer*. 2013;60:1513–1519.
- Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. *N Engl J Med*. 2012;367:1487–1496.
- Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. *J Clin Oncol*. 2017;35:3002–3009.
- Foundation for the Accreditation of Cellular Therapy (FACT). Factweb.org. 2018. Available at: <http://www.factweb.org/forms/store/CommercePlusFormPublic/search?action=Publications>. Accessed 14 February 2018.
- National Marrow Donor Program. NMDP standards, 24th edition; 2018. Available at: <https://bethematch.org/about-us/global-transplant-network/standards/>. Accessed 14 February 2019.
- Fettah A, Özbek N, Özgür M, et al. Factors associated with bone marrow stem cell yield for pediatric allogeneic stem cell transplantation: the impact of donor characteristics. *Pediatr Transplant*. 2017;21:e12841.
- Anthias C, Billen A, Arkwright R, Szydlo RM, Madrigal JA, Shaw BE. Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. *Transfusion*. 2016;56:1052–1057.
- Lannert H, Able T, Becker S, et al. Optimizing BM harvesting from normal adult donors. *Bone Marrow Transplant*. 2008;42:443–447.
- Shaw BE, Logan BR, Kiefer DM, et al. Analysis of the effect of race, socioeconomic status, and center size on unrelated National Marrow Donor Program donor outcomes: donor toxicities are more common at low-volume bone marrow collection centers. *Biol Blood Marrow Transplant*. 2015;21:1830–1838.
- Fagioli F, Quarello P, Pollichi S, et al. Quality of harvest and role of cell dose in unrelated bone marrow transplantation: an Italian Bone Marrow Registry-Gruppo Italiano Trapianto di Midollo Osseo study. *Hematology*. 2014;19:1–9.
- Kao RH, Li CC, Shaw CK, et al. Correlation between characteristics of unrelated bone marrow donor and cell density of total nucleated cell in bone marrow harvest. *Int J Hematol*. 2009;89:227–230.
- Wang TF, Chu SC, Chen SH, et al. The effect of different harvest strategies on the nucleated cell yields of bone marrow collection. *Biol Blood Marrow Transplant*. 2011;17:351–355.
- Witt V, Pichler H, Fritsch G, Peters C. Multiple small versus few large amount aspirations for bone marrow harvesting in autologous and allogeneic bone marrow transplantation. *Transfus Apher Sci*. 2016;55:221–224.
- Shyr DC, Hsieh FF, Reems JA. Single center experience with total nucleated cell, CD34 and CD3 cell yield from bone marrow harvests in both adult and pediatric donors. *Biol Blood Marrow Transplant*. 2018;24:S120.
- Remberger M, Ringdén O, Mattsson J. Bone marrow aspiration technique has deteriorated in recent years. *Bone Marrow Transplant*. 2015;50:1007–1009.
- Richart J, McCormick K, Weaver CE, Kelly J, Pincus SM. The role of total nucleated cell concentration in bone marrow collections. *Biol Blood Marrow Transplant*. 2017;23:S192.
- Helgestad J, Rosthøj S, Johansen P, Varming K, Ostergaard E. Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukaemia. *Pediatr Blood Cancer*. 2011;57:224–226.
- Fabrizio V, Armeson K, Warneke S, Jaroscak JJ, Hudspeth M. Trends in cell dose requests for a NMDP bone marrow collection center. *Biol Blood Marrow Transplant*. 2017;23:S408.
- Jaddini E, Hjortholm N, Snarski E. Effective pain reduction during bone marrow biopsy and aspiration—technique over experience. *Acta Haematol Pol*. 2016;47:226–231.
- Pruszczak K, Skwierawska K, Krol M, et al. Bone marrow harvest from unrelated donors—up-to-date methodology. *Eur J Haematol*. 2017;99:357–365.